NCT07457684

Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin

Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin (the BONANZA Study)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 846 (actual)
• Sponsor: Clinique Ovo · Industry
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

The goal of this retrospective study is to compare the effectiveness and cost-effectiveness of two mixed ovarian stimulation protocols in women undergoing in vitro fertilization (IVF). The main questions it aims to answer are: * Does the combination of follitropin delta + HP-hMG result in a higher number of utilizable blastocysts per treatment cycle compared to follitropin alfa + HP-hMG? * Does the follitropin delta based mixed protocol reduce total gonadotropin dose and cost per usable blastocyst while maintaining or improving pregnancy outcomes? Researchers will compare follitropin alfa (Gonal-F®) + HP-hMG (Menopur®) with follitropin delta (Rekovelle®) + HP-hMG (Menopur®) to determine which protocol improves ovarian response, embryology outcomes, pregnancy rates, and overall treatment cost-efficiency.

Conditions

• IVF Outcomes
• OVARIAN STIMULATION

Timeline

• Start date: 2025-12-05
• Primary completion: 2025-12-15
• Completion: 2025-12-15
• First posted: 2026-03-09
• Last updated: 2026-03-09

Locations

1 site across 1 country: Canada